Entera Bio raises ~$275M in private placement for phase 3 osteoporosis trial; BVF gets board seats

Entera Bio Ltd.

Raised ~$275M via private placement of 122.96M shares and 11.84M pre-funded warrants at $2.04/share.
Proceeds to fund phase 3 registrational study of EB613 for postmenopausal osteoporosis and working capital.
BVF Partners (lead investor) gets right to designate two board directors, subject to ownership thresholds.
Two current independent directors (Haya Taitel and Yonatan Malca) to resign or not stand for reelection as part of succession plan.
Company to seek shareholder approval for equity plan increase and executive grants at special meeting in Q4 2026.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Haya Taitel

Director

ENTXW · Entera Bio Ltd.

Filed: July 28, 2026, 4:12 PM ET

Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.

Departed

Yonatan Malca

Director

ENTXW · Entera Bio Ltd.

Filed: July 28, 2026, 4:12 PM ET

Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Haya Taitel departed as Director at Entera Bio Ltd..

Action: resign or not stand for reelection
Role: Director

Exact text from the filing

Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Yonatan Malca departed as Director at Entera Bio Ltd..

Action: resign or not stand for reelection
Role: Director

Exact text from the filing

Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.

View on SEC.gov

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-003617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.